Show simple item record

dc.contributor.authorLabarca, Gonzalo
dc.contributor.authorHenríquez Beltrán, Mario
dc.contributor.authorLamperti, Liliana
dc.contributor.authorNova Lamperti, Estefania
dc.contributor.authorSanhueza, Sergio
dc.contributor.authorCabrera, Camilo
dc.contributor.authorQuiroga, Romina
dc.contributor.authorAntilef, Barbara
dc.contributor.authorOrmazábal, Valeska
dc.contributor.authorZúñiga, Felipe
dc.contributor.authorCastillo, Daniela
dc.contributor.authorHorta, Gloria
dc.contributor.authorEnos, Daniel
dc.contributor.authorLastra, Jaime
dc.contributor.authorGonzález, Jessica
dc.contributor.authorTarga, Adriano
dc.contributor.authorBarbé Illa, Ferran
dc.date.accessioned2022-07-25T07:14:54Z
dc.date.available2022-07-25T07:14:54Z
dc.date.issued2022
dc.identifier.issn2296-858X
dc.identifier.urihttp://hdl.handle.net/10459.1/83668
dc.description.abstractObjective: To determine the association between Obstructive Sleep Apnea (OSA) with long-term symptoms and inflammatory cytokines, exploring the changes between 4-months and 1-year after COVID-19 infection. Methods: We conducted an observational, prospective cohort study, including patients ≥18 years old with confirmed diagnosis of COVID-19 between April to July 2020. All participants underwent two clinical follow-up visits, the first at 4-months (Visit 1) and the second at 1 year, after SARS-CoV-2 infection (Visit 2). Plasma glucose, total cholesterol, HDL, and triglycerides. Regarding pulmonary function, spirometry and lung diffusion capacity tests were assessed. For mental and neurocognitive evaluation, a short-form (SF-12), Beck depression and Hospital-Anxiety depression questionnaires were conducted at both time-points, whereas the Montreal Cognitive assessment was conducted during the second follow-up. Regarding to sleep evaluation, Epworth Sleepiness Scale, Insomnia Severity index and STOP-BANG questionnaire were conducted. Additionally, a home sleep apnea test and 7-day wrist actigraphy were performed in all participants. Inflammatory cytokines were measured using an inflammatory cytokine bead array kit. p-values < 0.05 were considered statistically significant and statistical analyses were performed using R software. Results: A total of 60 patients were included in the first follow-up, from which 57 completed the second follow-up. The mean age was 46.4 years-old (SD ± 13.1) and 53.3% were male. 30% of cases reported mild COVID-19 infection, 28.3% with moderate illness, and 41.6% with severe illness. Moreover, 56.6% of them were admitted to the ICU. Regarding to metabolic values, the OSA group showed higher values of insulin resistance (IR) (27%), systolic blood pressure (SBP) 135.2 (±19.1), dyslipidemia (67.5%), total cholesterol 202.1 (±60.5), triglycerides 176.1 (±119.0) and HOMA-IR 9.0 (±18.8) in comparison with the non-OSA group. 1 year after COVID-19 infection, DLCO test remains abnormal in OSA patients (25% OSA vs. 3.6% non-OSA, p = 0.02). Finally, those participants with OSA who develop ARDS reported an adjusted OR 20.4 (95%-CI, 1.04-504) risk of neurocognitive impairment. Discussion: Among patients with previous COVID-19, OSA impact the development of incident glycemic, neurocognitive impairment, and abnormal functional pulmonary changes that persist up to 1 year since acute phase.ca_ES
dc.description.sponsorshipThis study was supported by the Agencia Nacional de Investigación y Desarrollo (ANID, COVID1005), Chilean Government. GL declares funding for research by the American Academy of Sleep Medicine (AASM, 254-FP-21). JG, FB, and AT declare funded by ISCIII (CIBERESUCICOVID, COV20/00110). EN-L, SS, CC, RQ and BA were funded by Fondecyt 1211480 and COVID-19 Genomics Network (C19-GenoNet) ACT210085. Figure 1 was created with BioRender.com and Flow Cytometer was funded by EQM150061 (FONDEQUIP-ANID).ca_ES
dc.language.isoengca_ES
dc.publisherFrontiers Mediaca_ES
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.3389/fmed.2022.884218ca_ES
dc.relation.ispartofFrontiers in Medicine, 2022, vol. 9ca_ES
dc.rightscc-by (c) Authors 2022ca_ES
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subjectCOVID-19ca_ES
dc.subjectCytokinesca_ES
dc.subjectNeurocognitive impairmentca_ES
dc.subjectObstructive sleep apneaca_ES
dc.subjectSymptomsca_ES
dc.titleImpact of Obstructive Sleep Apnea (OSA) in COVID-19 Survivors, Symptoms Changes Between 4-Months and 1 Year After the COVID-19 Infectionca_ES
dc.typeinfo:eu-repo/semantics/articleca_ES
dc.identifier.idgrec032551
dc.type.versioninfo:eu-repo/semantics/publishedVersionca_ES
dc.rights.accessRightsinfo:eu-repo/semantics/openAccessca_ES
dc.identifier.doihttps://doi.org/10.3389/fmed.2022.884218


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record

cc-by (c) Authors 2022
Except where otherwise noted, this item's license is described as cc-by (c) Authors 2022